Who's doing what on EMA call for generics suspension after Indian CRO data manipulation
This article was originally published in SRA
The European Commission says that "within roughly a month" it will make its decision on the European Medicines Agency's recommendation that hundreds of formulations and strengths of generic medicines whose European marketing authorizations relied on clinical studies performed by Indian contract research organization GVK Biosciences be suspended in the EU1.
You may also be interested in...
Indian clinical trial approvals appear to be on the downswing despite government moves to boost the troubled sector, as regulatory uncertainty and negative publicity continue to undermine confidence in the industry.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.